AIDS OPPORTUNISTIC INFECTIONS DRUG DESIGN

艾滋病机会性感染药物设计

• 批准号: 6586754
• 负责人: DAVID W BORHANI
• 金额: $ 14.32万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-03-01 至 2003-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6586754
• 关键词: AIDS; bioimaging /biomedical imaging; biomaterials; biomedical resource; immunology; infection; inflammation; lymphatic system; proteins; radiography; structural biology; virus

Pneumocystis carinii pneumonia (PCP) is the leading killer of patients with AIDS. Similarly, Toxomplasma gondii, a pervasive parasitic protozoan, causes significant morbidity and mortality among AIDS patients. Current treatment regimens for both P. carinii and T. gondii infections often produce severe side effects, leading to the cessation of therapy. It is widely recognized that new drugs having novel mechanisms of action are urgently needed for the treatment of PCP and toxoplasmosis. Building upon prior medicinal chemistry research, we have initiated two structure-based drug design programs to make improved inhibitors of T. gondii hypoxanthine-guanine phosphoribosyltransferase (HGPRT), T. gondii dihydrofolate reductase-thymidylate synthase (DHFR-TS) and P. carinii DHFR.

卡氏肺囊虫肺炎（PCP）是肺炎的头号杀手 艾滋病患者。 同样，弓形虫（Toxomplasma gondii）是一种普遍存在的 寄生原生动物，导致显着的发病率和死亡率 艾滋病患者。 目前卡氏疟原虫和 T.​​ 卡氏疟原虫的治疗方案。 弓形虫感染通常会产生严重的副作用，导致 停止治疗。 人们普遍认为新药具有 迫切需要新的作用机制来治疗 PCP 和弓形体病。 以先前的药物化学为基础 研究中，我们启动了两个基于结构的药物设计项目 改进弓形虫次黄嘌呤-鸟嘌呤抑制剂 磷酸核糖转移酶 (HGPRT)、弓形虫二氢叶酸 还原酶胸苷酸合酶 (DHFR-TS) 和 P. carinii DHFR。